

ASTRAZENECA PLC
Form 6-K
June 26, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of June 2015

Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____

AstraZeneca PLC - Change in ADS ratio

Edgar Filing: ASTRAZENECA PLC - Form 6-K

AstraZeneca PLC (the "Company") today announces an intended ratio change to its NYSE-listed sponsored Level 2 American Depositary Receipt ("ADR") programme. The current ratio is one (1) American Depositary Share ("ADS") per one (1) Ordinary Share. The new ratio will be two (2) ADSs per one (1) Ordinary Share. The expected effective date for the ratio change is 27 July 2015. There will be no change to the underlying Ordinary Shares.

ADS holders at the close of business New York time on the record date, 22 July 2015, will receive a distribution of one additional ADS for every ADS held. The new ADSs are expected to be distributed on 24 July 2015. No action is required by ADS holders to effect this change.

Contact details for Citibank, N.A., the Company's ADR depository, can be found below.

A C N Kemp
Company Secretary

26 June 2015

CONTACT

Citibank Shareholder Services

| | |
|---|---|
| PO Box 43077 Providence RI 02940-3077 US | Tel (toll free in the US): +1-888-697-8018 Tel (outside the US): +1-781-575-4555 |
|---|---|

Media Enquiries

| | |
|------------------|---------------------------------|
| Esra Erkal-Paler | +44 20 7604 8030 (UK/Global) |
| Jacob Lund | +46 8 553 260 20 (Sweden) |
| Michele Meixell | + 1 302 885 6351 (US) |

Investor Enquiries

| | | | |
|------------------------|--|---------------------|-------------------------|
| UK | | | |
| Thomas Kudsk Larsen | | +44 20 7604 8199 | mob: +44 7818 524185 |
| Eugenia Litz | Respiratory, Inflammation and Autoimmunity | +44 20 7604 8233 | mob: +44 7884 735627 |
| Nick Stone | | | |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | | |
|---------------------|--|------------------|----------------------|
| Karl Hård | Cardiovascular and Metabolic Disease | +44 1763 263 994 | mob: +44 7717 618834 |
| | Oncology | +44 20 7604 8123 | mob: +44 7789 654364 |
| Craig Marks | Infection, Neuroscience and Gastrointestinal Disease | +44 20 7604 8591 | mob: +44 7881 615764 |
| | | +44 20 7604 8126 | mob: +44 7827 836825 |
| Christer Gruvris | | | |
| US Dial / Toll-Free | | 301-398-3251 | 866-381-7277 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 26 June 2015

By: /s/ Adrian Kemp
Name: Adrian Kemp
Title: Company Secretary